@FiercePharma: FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine. FierceVaccines story | Follow @FiercePharma
@CarlyHFierce: ICYMI yesterday: Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti. Article | Follow @CarlyHFierce
> GlaxoSmithKline ($GSK) has rolled out Nucala, a treatment for patients with a type of severe asthma, in the U.S. Release
> The U.K.'s cost-effectiveness gatekeepers are advocating for a tailored approach to Type 2 diabetes treatment. More
> Negative news about the risks or side effects of statin drugs prompts people to ratchet back their use of the drug, increasing risks of heart attacks and strokes, a new study found. Report
> Horizon Pharma ($HZNP) nabbed European approval for Ravicti, its new add-on drug for urea cycle disorders. Report
> The market for opioid-induced constipation treatments will swell to $650M by 2019, research and consulting firm GlobalData predicts. More
Medical Device News
@FierceMedDev: ICYMI yesterday: Boston Sci receives FDA and CE mark approval of its thrombectomy catheter for deep vein thrombosis. Story | Follow @FierceMedDev
@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Article | Follow @VarunSaxena2
@EmilyWFierce: $GILD: "Let's not fold to advocacy pressure in 2014." More from the WSJ | Follow @EmilyWFierce
> Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Story
> Theranos asked military general for help tamping down 'misinformation' from the DOD. Article
Biotech News
@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech
@JohnCFierce: Zafgen shares crash after second patient in pivotal obesity study dies. Report | Follow @JohnCFierce
@DamianFierce: Knicks Porzingis jersey not yet for sale so I'm just getting his name tattooed on my back as a placeholder. | Follow @DamianFierce
> Boehringer joins MD Anderson's cadre of cancer collaborators with pancreatic partnership. Report
> Ex-GSK cancer chief Paoletti scores $29M war chest for multiple myeloma startup Kesios. Article
> Outsmarting tumors: Biotech startup maestro Heyman fuels ORIC with $53M round. More
> MedDay misses endpoint in PhIII multiple sclerosis vision loss trial. Story
Biotech Research News
> UCLA scientist points to pregnancy hormone as a safe, simple MS therapy. Article
> Scripps team partially corrects impact of a cystic fibrosis mutation. More
> Rockefeller researchers study a new approach to controlling nicotine addiction. Story
> BRCA1 is back in the spotlight, this time for Alzheimer's disease. Report
> New class of antimicrobials may be highly potent against MRSA. Article
Vaccines News
> Parents may be misled by inaccurate HPV vaccine websites, report says. Item
> NIAID to bring Chikungunya vaccine into Phase II. Report
> Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII. Article
> Sanofi, Shantha to supply polio vaccines for India's universal immunization scheme. More
> FDA approves Seqirus' Fluad, the first U.S. boosted flu vaccine. Story
Pharma Marketing News
> Novo Nordisk strikes back with SGLT2-beating data on Victoza. Story
> Study finds no shortage of misleading HPV vaccine websites. Item
> Amgen biosim advances toward battle with AbbVie's mega-selling Humira. Report
> Pfizergan headed for top of ad-spend leaderboard--and not just in pharma. Article
> Ex-Sanofi staffer adds new allegations to last year's kickback suit. More
And Finally... Forget Adderall for a workplace boost; some Silicon Valley workers are reportedly taking small doses of the psychedelic drug LSD to make themselves more productive. Report